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OBJECTIVES: Biologic treatments had dramatically changed the therapeutics, out-
comes and cost of management of psoriasis, a common chronic disease that
strongly affects quality of life of patients. The aim of this study was to assess the
cost-effectiveness of biologic alternatives currently available in Mexico for treat-
ment ofmoderate to severe psoriasis from an institutional perspective.METHODS:
A decision-tree model was developed to simulate the clinical course of patients
treated with etanercept, adalimumab, infliximab or ustekinumab as first-line ther-
apies, as well as treatment associated costs (2-year timeframe with a 5% annual
discount rate). Effectiveness measures were the proportion of patients reaching
75% improvement in the Psoriasis Area and Severity Index (PASI-75) and quality
adjusted life years gained (QALY=s). Costs considered included: biologics drugs,
concomitantmedication,medical follow-up and side effectsmanagement. Clinical
response of alternatives was extracted from published literature, while unit costs
were collected from Instituto Mexicano del Seguro Social (IMSS) official databases.
Probabilistic sensitivity analyses were completed. RESULTS: After two years, the
proportions of patients reaching PASI-75 were 59%, 62.1%, 62.7%, and 64.5% for
adalimumab, etanercept, infliximab and ustekinumab, respectively (p0.077,
Friedman test); QALY=s associated to each alternative were: 1.5554, 1.5633, 1.5650
and 1.5695, respectively (p0.392, Friedman test). Given that in the timeframe
considered there are no differences between effectiveness of therapies, a cost-
minimization rather than a cost-effectiveness analysis was performed. The ex-
pectedmean costs per patient were: US$27,281.95, US$25,929.85, US$31,542.76 and
US$38,050.59, respectively. Etanercept is US$1,352.1(5.1%) less costly compared to
adalimumab; US$5,612.91(17.8%) compared to infliximab and US$12,120.74
(46.74%) compared to ustekinumab (the most costly alternative). CONCLUSIONS:
Given that effectiveness of the biologic treatments analyzed is similar over the
time-horizon used, etanercept treatment represents the less expensive alternative
for the management of moderate and severe psoriasis at IMSS.
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COST-EFFECTIVENESS ANALYSIS OF FORMULARY MANAGEMENT STRATEGIES
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OBJECTIVES: To determine which formulary management strategy of ophthalmic
prostaglandins (PGs) is the most cost-effective from the perspective of a managed
care organization (MCO) over one year. METHODS: This cost-effectiveness model
contains eight unique arms, which reflect different formulary management strat-
egies for the PGs (bimatoprost, latanoprost, travoprost). Three arms examine the
cost-effectiveness of each PG as first-line therapy, with timolol added as second-
line therapy for patients not reaching goal intraocular pressure (IOP). The next
three arms examine first-line therapy with timolol, an alternative and less costly
primary therapy, with a preferred PG as second-line therapy. An additional arm
examines not selecting a preferred PG as first-line therapy with timolol as second-
line therapy, and the final arm examines timolol as first-line therapy, but does not
select a preferred PG as second-line. An effectively treated patient was defined as a
patient achieving an IOP less than 18 mm Hg after three months of therapy. If
patients were unable to reach goal IOP with secondary-line therapy, dorzolamide
was added. Patients unable to tolerate therapy or achieve goal IOP required addi-
tional physician visits. Costs included prescription medications and physician vis-
its in 2010 US dollars. RESULTS: The cost-effectiveness ratios (CER) for first-line
therapy with a preferred PG were $815.13, $961.71, and $889.13 per effectively
treated patient for bimatoprost, latanoprost, and travoprost, respectively. The
CERs for first-line therapy with timolol, followed by a preferred PG, were $436.77,
$499.77, and $462.21 for bimatoprost, latanoprost, and travoprost, respectively. If a
preferred PG was not selected, the CERs were $910.95 for first-line therapy and
$477.77 for second-line therapy. Sensitivity analyses showed that reducing the
price of latanoprost by 9 percent and travoprost by 3 percent yields equivalent CERs
as bimatoprost. CONCLUSIONS: Timolol followed by a bimatoprost is the most
cost-effective of the eight treatment strategies examined in this model.
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OBJECTIVES: A literature review identified that constrained resource models of
service delivery and organisation do not include patient-based outcomes. The aim
of this study is to develop an evidence-based framework representing costs and
health benefits, to inform best use of constrained health care services in a routine
clinical setting.METHODS:Adiscrete event simulation (DES)model was developed
to represent the use of glaucoma services at the Royal Adelaide Hospital. The DES
describes disease progression and pathways of care, where disease progression is
influenced by the frequency and content of hospital visits, and vice versa. Individ-
uals, who are competing for access to hospital services, are assigned characteris-
tics that represent relevant patient and disease characteristics. Across all individ-
uals, these data inform the demand for services over time, which is combinedwith
information on the supply of available resources within the system to analyze
alternative approaches to the use of available resources. RESULTS: The base case
model has been validated against hospital data representing both process and
clinical measures over time. Analysis of the model shows variation in the total
QALYs gained by cohorts of glaucoma patients over their remaining lifetime, ac-
cording to alternative treatment decision algorithms (e.g. medication versus sur-
gical intervention); surveillance and imaging algorithms (e.g. variation in relative
follow-up schedules for high and low priority patients). CONCLUSIONS: The ap-
plied framework illustrates the potential value of DES in modelling the costs and
health benefits of alternative approaches to organising scarce physical resources,
providing estimates of health gains that can be achieved in the absence of the
introduction of new technologies.
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OBJECTIVES:Macular edema (ME) following retinal vein occlusion (RVO) is a com-
mon cause of vision loss. The objective of this research was to assess the lifetime
incremental cost-effectiveness of dexamethasone intravitreal implant 0.7mg (DEX)
treatment versus observation for ME following central or branch RVO (CRVO or
BRVO) from aUS payer perspective.METHODS:An Excel-basedMarkovmodel with
6 heath states based on visual acuity (VA) plus one absorbing (Death) state was
developed. Transition matrices were derived using individual patient-level data
pooled from two identical phase 3 studies. Enrolled study patients at baseline had
mean age of 65 years and study-eye VA of 20/80. DEX patients were assumed to
receive up to 6-treatments over 3 years. Direct medical costs included drug, proce-
dure,maintenance care, and adverse events. Additional directs costs andmortality
was assigned to patients who became legally blind (20/200 in BSE). Utility scores
were directly calculated from study data via the Visual Function Questionnaire –
Utility Index and health states differentially valued bywhether the treated eyewas
the better- (BSE) or worse-seeing-eye (WSE). 90% of patients were assumed to have
RVO in their WSE at model entry and a time-dependent risk of fellow eye occur-
rence (FEO) was incorporated. Costs and outcomes were discounted at 3%. Deter-
ministic and probabilistic sensitivity analyses were conducted. RESULTS: Refer-
ence case ICERswere $23,416 and $20,597 perQALY for BRVOandCRVO (respectively);
and sensitive to the percent of patients incurring the RVO in the BSE, risk of FEO, and
cost of vision loss. Probabilistic sensitivity analyses demonstrated that the ICERs fall
below a threshold of $50,000 per QALY in 87% and 92% of simulations for BRVO and
CRVO, respectively. CONCLUSIONS: Using a threshold of $50,000, DEX treatment
compared to observation is supported as a cost-effective treatment option for ME
following BRVO or CRVO.
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OBJECTIVES: Assess cost-utility of ranibizumab (Lucentis®) in wet-AMD based on
real-life evidence regarding quality of life, treatment patterns and effectiveness
collected in the Belgian observational HELIOS study including 253 patients treated
with ranibizumab after reimbursement approval. METHODS: An existing model,
developed for clinical trial-based analyses, was extended to include a real-life
ranibizumab arm. This 10-year MS-Excel Markovmodel with 5 visual acuity (VA)
levels and 1 death state predicts VA in patients treated with ranibizumab, Visudyne®
photodynamic therapy (PDT) or best supportive care (BSC). Transition probabilities
and treatment frequency for ranibizumab (on average 5 injections during year 1)
were provided by theHELIOS trial (1-year interim data). For comparators these data
were obtained from several clinical trials (ANCHOR, MARINA, PIER and TAP). Base-
line characteristics and utilities correlating with treated-eye VA were obtained
from the HELIOS study. Two-year treatment duration was modelled, followed by
BSC. Costs (2010) from the perspective of the health care payer  social services 
patient were obtained from literature and expert opinion. Costs (3%) and outcomes
(1.5%) were discounted. Sensitivity analyses covered variability in efficacy, costs,
treatment frequency and utilities. RESULTS:Vision gain in real-lifewas in linewith
PRN clinical data but lower than observed in monthly-dosing clinical trials. Injec-
tion frequency and costs were lower in real-life than anticipated from ranibizumab
clinical trials. Base-case analyses versus BSC (MARINA, PIER and TAP) consistently
revealed cost-utility of ranibizumab, with results ranging from dominance to
8,367€/QALY. Base-case analyses versus PDT (PIER and TAP) suggested dominance
of ranibizumab. Results were most sensitive to the cost of blindness and time
horizon, but remained generally within acceptable limits. At an acceptability
threshold of 35,000€/QALY, the probability that real-life ranibizumab is cost-effec-
tive ranged from 84% to 100%. CONCLUSIONS: Real-life use of ranibizumab in
wet-AMD appeared highly cost-effective compared to BSC and PDT.
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